Stephana Patton Net Worth

The estimated Net Worth of Stephana Eilene Patton is at least $1.28 Million dollars as of 22 April 2019. Stephana Patton owns over 1,000 units of Eiger BioPharmaceuticals Inc stock worth over $6,900 and over the last 7 years he sold EIGR stock worth over $0. In addition, he makes $1,272,320 as Chief Compliance Officer, General Counsel, and Corporate Secretary at Eiger BioPharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Stephana Patton EIGR stock SEC Form 4 insiders trading

Stephana has made over 4 trades of the Eiger BioPharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of EIGR stock worth $11,030 on 22 April 2019.

The largest trade he's ever made was exercising 27,500 units of Eiger BioPharmaceuticals Inc stock on 18 December 2018 worth over $47,438. On average, Stephana trades about 4,523 units every 55 days since 2017. As of 22 April 2019 he still owns at least 4,000 units of Eiger BioPharmaceuticals Inc stock.

You can see the complete history of Stephana Patton stock trades at the bottom of the page.

Stephana Patton biography

Dr. Stephana Eilene Patton Ph.D. J.D. serves as Chief Compliance Officer, General Counsel, Corporate Secretary of the Company. Dr. Patton brings twenty years of legal experience to Eiger, and was most recently General Counsel, Corporate Secretary, and Chief Compliance Officer at BioTime, Inc., responsible for all legal and compliance matters at BioTime and its subsidiaries. Previously, Dr. Patton was Vice President, General Counsel, and Commercial Compliance Officer at BioDelivery Sciences International, Inc. Dr. Patton began her pharmaceutical industry career at Salix Pharmaceuticals, Inc., where she was Vice President of Intellectual Property and Licensing, until the company was acquired by Valeant, Inc. in 2015.

What is the salary of Stephana Patton?

As the Chief Compliance Officer, General Counsel, and Corporate Secretary of Eiger BioPharmaceuticals Inc, the total compensation of Stephana Patton at Eiger BioPharmaceuticals Inc is $1,272,320. There are 2 executives at Eiger BioPharmaceuticals Inc getting paid more, with David Cory having the highest compensation of $2,871,850.

How old is Stephana Patton?

Stephana Patton is 49, he's been the Chief Compliance Officer, General Counsel, and Corporate Secretary of Eiger BioPharmaceuticals Inc since 2019. There are 16 older and 2 younger executives at Eiger BioPharmaceuticals Inc. The oldest executive at Eiger BioPharmaceuticals Inc is Dr. Colin Hislop, 63, who is the Sr. VP of Clinical & Devel. Operations.

What's Stephana Patton's mailing address?

Stephana's mailing address filed with the SEC is C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE, CA, 94005.

Insiders trading at Eiger BioPharmaceuticals Inc

Over the last 9 years, insiders at Eiger BioPharmaceuticals Inc have traded over $3,017,304 worth of Eiger BioPharmaceuticals Inc stock and bought 780,533 units worth $4,706,203 . The most active insiders traders include Richard A Kayne, Edgar Engleman, and Partners X Lp Inter West Ma.... On average, Eiger BioPharmaceuticals Inc executives and independent directors trade stock every 70 days with the average trade being worth of $47,232. The most recent stock trade was executed by Richard A Kayne on 31 October 2023, trading 278,239 units of EIGR stock currently worth $72,342.

What does Eiger BioPharmaceuticals Inc do?

eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.

Complete history of Stephana Patton stock trades at Cutera Inc and Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals Inc executives and stock owners

Eiger BioPharmaceuticals Inc executives and other stock owners filed with the SEC include:

• David Cory,
  President, Chief Executive Officer, Director
• David Apelian,
  Director
• Stephana Patton,
  Chief Compliance Officer, General Counsel, Corporate Secretary
• Sriram Ryali,
  Chief Financial Officer
• David A. Cory M.B.A., R.Ph., R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• James Shaffer,
  Chief Business Officer
• David A. Cory R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• Eldon C. Mayer III, M.B.A.,
  Exec. VP & Chief Commercial Officer
• Sriram Ryali M.B.A.,
  Chief Financial Officer
• Christine Murray,
  Independent Director
• Thomas Dietz,
  Independent Chairman of the Board
• Amit Sachdev,
  Independent Director
• Evan Loh,
  Independent Director
• Eldon Mayer,
  Executive Vice President, Chief Commercial Officer
• Jeffrey Glenn,
  Independent Director
• Dr. Evan Loh,
  CEO of Paratek Pharmaceuticals & Director
• Dr. Jeffrey S. Glenn,
  Founder, Scientific Advisor & Independent Director
• Dr. Stephana E. Patton J.D., Ph.D.,
  Consultant
• Erik Atkisson,
  Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Dr. Colin Hislop,
  Sr. VP of Clinical & Devel. Operations
• Rich Franco M.B.A.,
  Sr. VP & Progeria Program Lead
• Dr. Ingrid C. Choong,
  Sr. VP of Clinical Devel.
• Charles Bramlage,
  Director
• Edgar Engleman,
  Director
• Joanne Quan,
  Chief Medical Officer
• Eduardo Bruno Martins,
  SVP, Liver and Infectious Dise
• Ventures Vi, Llc Vivo Ventu...,
  
• James H Welch,
  Chief Financial Officer
• Nina S Kjellson,
  Director
• Kim Sablich,
  
• Partners X Lp Inter West Ma...,
  
• Ingrid Choong,
  Chief Business Officer
• Erik Atkisson,
  GC & Chief Compliance Officer
• Lisa Kelly Croswell,
  
• James Vollins,
  General Counsel
• Leen Kawas,
  
• Richard A Kayne,